ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
MWN-AI** Summary
ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on innovative therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced its participation in the 8th Annual Evercore Healthcare Conference. CEO Neil Warma will engage in a fireside chat and one-on-one investor meetings on December 2, 2025, with the discussion scheduled for 3:25 PM ET. A live webcast will be accessible on ProMIS’s website and available for 30 days post-event.
The company centers on developing therapeutic antibodies and vaccines that selectively target toxic oligomers—misfolded proteins implicated in the progression of neurodegenerative diseases such as AD, ALS, and Parkinson’s disease. ProMIS’s proprietary EpiSelect™ discovery engine identifies Disease Specific Epitopes (DSEs) on these proteins, a pivotal advancement that could lead to more effective treatments while minimizing unintended effects.
ProMIS's flagship candidate, PMN310, is a humanized monoclonal antibody engineered specifically to target toxic amyloid-beta oligomers (A?O) without impacting less harmful fibrils or monomers. This unique targeting may reduce the risk of amyloid-related imaging abnormalities (ARIA), which are often associated with traditional amyloid-targeting therapies. PMN310 received Fast Track designation from the U.S. FDA in July 2025 and is currently being evaluated in the Phase 1b PRECISE-AD trial. This study focuses on the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and early-stage AD.
ProMIS Neurosciences aims to leverage its innovative platform and clinical trials not only to advance the treatment of Alzheimer’s but also to pave the way for breakthroughs in therapies for various misfolded protein diseases. For further information, visit www.promisneurosciences.com.
MWN-AI** Analysis
ProMIS Neurosciences (Nasdaq: PMN) is positioning itself as a frontrunner in the search for innovative therapies for neurodegenerative diseases such as Alzheimer’s. As the company prepares for its participation at the 8th Annual Evercore Healthcare Conference on December 2, 2025, it presents an opportunity for investors to analyze potential market movements based on recent developments and ongoing trials.
The highlight of ProMIS' strategy is the lead candidate PMN310, a humanized monoclonal antibody specifically designed to target toxic amyloid-beta oligomers, while minimizing off-target binding and associated risks. With its recent Fast Track designation from the FDA and positive preliminary data from the Phase 1a trial, ProMIS is gaining traction in a market ripe for innovative solutions to Alzheimer’s disease’s complex pathology. The ongoing Phase 1b PRECISE-AD trial aims to provide valuable insights and solid data regarding PMN310’s safety profile and efficacy.
In the broader context of the biotech sector focused on neurodegenerative diseases, there’s a growing sentiment that unique mechanisms, such as those employed by the EpiSelect™ platform, could become increasingly valuable. Investors should consider that the ability to selectively target misfolded proteins could differentiate ProMIS from competitors that have faced challenges with traditional amyloid-focused therapies.
As of now, the biotechnology landscape remains volatile, particularly regarding clinical trial outcomes and regulatory approvals. Investors should maintain a cautious yet optimistic stance, leveraging volatility for potential entry points, especially as results from the PRECISE-AD trial are expected to be pivotal for PMN310’s future trajectory.
Ultimately, ProMIS Neurosciences appears to be a compelling investment consideration for those looking to tap into the future of Alzheimer's therapy, given its innovative approaches and positive momentum within the clinical pipeline. Investors should closely monitor developments post-conference and trial outcomes as key indicators of ProMIS' market position and potential growth.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will be participating in a fireside chat and investor one-on-one meetings at the 8 th Annual Evercore Healthcare Conference on Tuesday, December 2nd, 2025.
The fireside chat will be held at 3:25pm Eastern Time and a live webcast of the presentation may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com . The webcast will be available for at least 30 days following the event.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
About PMN310 and the PRECISE-AD Trial for Alzheimer’s Disease (AD)
PMN310, the Company’s lead product candidate for the treatment of AD, is a humanized monoclonal antibody that has been designed to selectively target only the toxic oligomers, avoiding plaque, thereby potentially reducing or eliminating amyloid-related imaging abnormalities (ARIA) liability. In addition, because PMN310 may not be limited by off-target binding or side effects, PMN310 could potentially offer an improved efficacy profile over other amyloid-directed antibody therapeutics. PMN310 was granted Fast Track designation by the U.S. Food and Drug Administration in July 2025.
Based on the encouraging results from the Phase 1a trial ( NCT06105528 ) of PMN310, ProMIS initiated PRECISE-AD, a Phase 1b clinical trial in AD patients. PRECISE-AD ( NCT06750432 ) is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with Mild Cognitive Impairment due to AD and mild AD (Stage 3 and Stage 4 AD). PRECISE-AD will be the first study to examine the effects of a monoclonal antibody directed solely against A?O on biomarkers associated with AD pathology and clinical outcomes. Safety will be a primary outcome of the study with particular emphasis on assessing whether, as a non-plaque binder, PMN310 may have a reduced risk of ARIA. The study is powered to provide 95% confidence for detection of ARIA. The study has been designed with a sample size intended to provide sufficient power to provide meaningful insight into effects of PMN310 on biomarkers and clinical outcomes.
EpiSelect TM Drug Discovery Engine
Toxic misfolded proteins underlie the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Generation of therapeutic antibodies selectively targeting only disease-misfolded protein isoforms, while sparing normal or irrelevant isoforms of the same protein, has not yet been successfully achieved by conventional immunization strategies. ProMIS Neurosciences has developed a computational platform (EpiSelect TM ) to identify conformational epitopes that are uniquely exposed on toxic misfolded proteins, which can then be used to generate misfolding-speci?c antibodies or vaccine formulations. Application of the ProMIS platform produced PMN310, a clinical stage, humanized monoclonal antibody candidate that has been shown to be highly selective for toxic amyloid-beta oligomers (A?O) without signi?cant reactivity with amyloid-beta monomers or ?brils, thereby avoiding target distraction by these more abundant species, and potentially reducing the risk of brain edema and microhemorrhages associated with the targeting of vascular/parenchymal amyloid. Similarly, speci?c epitopes for alpha-synuclein toxic oligomers/soluble ?brils that drive synucleinopathies, and for pathogenic TDP-43 in ALS and FTD have been identified and lead candidate antibodies generated. The precise conformation of these epitopes has been translated into vaccines inducing an antibody response selective for pathogenic molecular species in preclinical mouse vaccination studies.
For further information:
Visit us at www.promisneurosciences.com
Please submit media inquiries to info@promisneurosciences.com
For Investor Relations, please contact:
Kaytee Bock Zafereo
katherine.bock@promisneurosciences.com
FAQ**
How does ProMIS Neurosciences Inc. PMN:CC plan to leverage the Fast Track designation granted for PMN3in accelerating its clinical development timeline for Alzheimer’s disease therapies?
What specific outcomes from the PRECISE-AD trial will ProMIS Neurosciences Inc. PMN:CC focus on to demonstrate the efficacy and safety of PMN310 against traditional amyloid-targeting therapies?
Can you explain how the EpiSelect™ platform of ProMIS Neurosciences Inc. PMN:CC differentiates its therapy development from conventional approaches in targeting neurodegenerative diseases?
What are the anticipated market implications for ProMIS Neurosciences Inc. PMN:CC if PMN310 proves successful in addressing amyloid-related imaging abnormalities (ARIA) compared to current Alzheimer's treatments?
**MWN-AI FAQ is based on asking OpenAI questions about ProMIS Neurosciences Inc. (NASDAQ: PMN).
NASDAQ: PMN
PMN Trading
-1.54% G/L:
$24 Last:
19,399 Volume:
$22.79 Open:
